A multi-center, open-label extension study to evaluate the long-term safety, tolerability, and efficacy of E2007 (perampanel) in patients with painful diabetic neuropathy (PDN) or post-herpetic neuralgia (PHN).
Phase of Trial: Phase II/III
Latest Information Update: 27 Jan 2016
At a glance
- Drugs Perampanel (Primary)
- Indications Diabetic neuropathies; Neuropathic pain; Postherpetic neuralgia
- Focus Therapeutic Use
- Sponsors Eisai Inc
- 15 Mar 2012 This trial is recruiting in Hungary and England.
- 15 Mar 2012 Additional locations (England, Germany, Hungary, Lithuania) added as reported by European Clinical Trials Database.
- 06 Mar 2012 Actual patient number is 262 and company (Eisai Inc) added as reported by ClinicalTrials.gov.